Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype

American Journal of Clinical Nutrition

Volumn 82, Issue 1, 2005, Pages 26-31

  Williams, Carolyn ^a   Kingwell, Bronwyn A ^a   Burke, Kevin ^a   McPherson, Jane ^a   Dart, Anthony M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Arterial stiffness; Folate therapy; Genetics; Homocysteine; Hypertension; MTHFR gene; Pulse pressure

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; PLACEBO; ANTIANEMIC AGENT; CHOLESTEROL; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; FOLIC ACID BLOOD LEVEL; GENOTYPE; HUMAN; MEAN ARTERIAL PRESSURE; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HYPERTENSION; VITAMIN SUPPLEMENTATION; BLOOD; BLOOD PRESSURE; GENETICS; GLUCOSE BLOOD LEVEL; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; VASCULAR RESISTANCE;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FOLIC ACID; GENOTYPE; HEMATINICS; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); VASCULAR RESISTANCE;

EID: 23444452249     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/82.1.26     Document Type: Article

References (57)

1. Parnetti L, Caso V, Santucci A, et al. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci 2004;25: 13-7.
2. Zylberstein DE, Bengtsson C, Bjorkelund C, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004;109:601-6.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274: 1049-57.
4. Zhou J, Moller J, Danielson CC, et al. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler Thomb Vasc Biol 2001;21:1470-6.
5. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745-9.
6. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
7. Wald DS, Laws M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
8. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237-41.
9. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004;109:369-74.
10. Charpiot P, Bescond A, Augier T, et al. Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hyrochlorothiazide. Matrix Biol 1998;17: 559-74.
11. Evans RW, Shaten BJ, Hamplel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997;17:1947-53.
12. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000;72:315-23.
13. Title LM, Cummings PM, Giddens K, Genest JJ, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36:758-65.
14. Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002;112:556-65.
15. Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and reduces blood pressure in smokers: a randomised controlled trial. J Intern Med 2002;252:497-503.
16. Symons JD, Mullick AE, Ensunsa JL, Ma AA, Rutledge JC. Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol 2002;22: 772-80.
17. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.
18. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-5.
19. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thomb Vasc Biol 2001;21:2046-50.
20. Kawashiri M, Kajinami K, Nohara A, Yagi K, Inazu A, Koizumi J. Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolaemia. Am J Cardiol 2000;86:840-5.
21. Mager A, Lalezari A, Shohat T, et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999;100:2406-10.
22. Verhaar MC, Wever RMF, Kastelein JJP, et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomised placebo-controlled trial. Circulation 1999;100: 335-8.
23. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999;34:2002-6.
24. Ferrier KE, Waddell TK, Gatzka CD, Cameron JD, Dart AM, Kingwell BA. Aerobic exercise training does not modify large-artery compliance in isolated systolic hypertension. Hypertension 2001;38:222-6.
25. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
26. Published errata appear in J Hypertens 2003;21:2203-4.
27. J Hypertens 2004;22:435.
28. Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
29. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316:894-8.
30. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
31. Malinow MR, Duell PB, Williams MA, et al. Short-term folic acid supplementation induces variable and paradoxical changes in plasma homocyst(e)ine concentrations. Lipids 2001;36(suppl):S27-32.
32. Lehmann KG, Gelman JA, Weber MA, Lafrades A. Comparative accuracy of three automated techniques in the noninvasive estimation of central blood pressure in men. Am J Cardiol 1998;81:1004-12.
33. Cameron JD, Dart AM. Exercise training increases total systemic arterial compliance in humans. Am J Physiol 1994;266:H693-701.
34. Liu Z, Brin K, Yin FC. Estimation of total arterial compliance: an improved method and evaluation of current methods. Am J Physiol 1986;251:H588-600.
35. Williams MR, Westerman RA, Kingwell BA, et al. Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab 2001;86:5389-95.
36. Cameron J. Estimation of arterial mechanics in clinical practice and as a research technique. Clin Exp Pharmacol Physiol 1999;26:285-94.
37. Chen CH, Ting CT, Nussbacher A, et al. Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. Hypertension 1996;27:168-75.
38. Kingwell BA, Berry KL, Cameron JD, Jennings GL, Dart AM. Arterial compliance increases after moderate-intensity cycling. Am J Physiol 1997;273:H2186-91.
39. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
40. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-6.
41. Nakano E, Higgins JA, Powers HJ. Folate protects against oxidative modification of human LDL. Br J Nutr 2001;86:637-9.
42. Wilkinson IB, MacCallum H, Cockroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002;53:189-92.
43. Nestel PJ, Chronopoulos A, Cehun M. Arterial stiffness is rapidly induced by raising the plasma homocysteine concentration with methionine. Atherosclerosis 2003;171:83-6.
44. Anderson JL, Muhlestein JB, Home BD, et al. Plasma homocysteine predicts mortality independently of traditionally risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-37.
45. Bescond A, Augier T, Chareyre C, Garcon D, Horneback W, Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commum 1999;263:498-503.
46. Chaussalet M, Lamy E, Foucault-Bertaud A, et al. Homocysteine modulates the proteolytic potential of human vascular endothelial cells. Biochem Biophys Res Commum 2004;316:170-6.
47. Holven KB, Halvorsen B, Schulz H, Aukrust P, Ose L, Nenseter MS. Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects. Eur J Clin Invest 2003;33:555-60.
48. Ashfield-Watt PA, Pullin CH, Whiting JM, et al. Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr 2002;76:180-6.
49. Duell PB, Malinow MR. Effects of folic acid on homocysteine in persons classified by methylenetetrahydrofolate reductase genotype. Am J Clin Nutr 1999;69:1287-9.
50. Malinow MR, Nieto F, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17:1157-62.
51. de Bree A, Verschuren WM, Bjorke-Monsen A-L, et al. Effect of the methylenetetrahydrofolate reductase 677C→T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 2003;77:687-93.
52. Benetos A, Safar M, Rudnichi A, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997;30:1410-5.
53. Kelly R, Fitchett D. Noninvasive determination of aortic input impedance and external left ventricular power output: a validation and repeatability study of a new technique. J Am Coll Cardiol 1992;20:952-63.
54. Watanabe H, Ohtsuka S, Kakihana M, Sugishita Y. Coronary circulation in dogs with an experimental decrease in aortic compliance. J Am Coll Cardiol 1993;21:1497-506.
55. Kass DA, Saeki A, Tunin RS, Recchia FA. Adverse influence of systemic vascular stiffening on cardiac dysfunction and adaptation to acute coronary occlusion. Circulation 1996;93:1533-44.
56. Kingwell BA, Waddell TK, Medley TL, Cameron JD, Dart AM. Large artery stiffness predicts ischaemic threshold in patients with coronary artery disease. J Am Coll Cardiol 2002;40:773-9.
57. Bryan J, Calvaresi E. Associations between dietary intake of folate and vitamins B-12 and B-6 and self-reported cognitive function and psychological well-being in Australian men and women in midlife. J Nutr Health Aging 2004;8:226-32.